Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The predictive power of baseline metabolic and volumetric [18F]FDG PET parameters with different thresholds for early therapy failure and mortality risk in DLBCL patients undergoing CAR-T-cell therapy.
Novruzov E, Peters HA, Jannusch K, Kobbe G, Dietrich S, Fischer JC, Rox J, Antoch G, Giesel FL, Antke C, Baermann BN, Mamlins E. Novruzov E, et al. Among authors: giesel fl. Eur J Radiol Open. 2024 Dec 17;14:100619. doi: 10.1016/j.ejro.2024.100619. eCollection 2025 Jun. Eur J Radiol Open. 2024. PMID: 39803388 Free PMC article.
First-in-human SPECT/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer.
Watabe T, Hatano K, Naka S, Sasaki H, Kamiya T, Shirakami Y, Toyoshima A, Cardinale J, Giesel FL, Isohashi K, Nonomura N, Tomiyama N. Watabe T, et al. Among authors: giesel fl. Eur J Nucl Med Mol Imaging. 2024 Dec 17. doi: 10.1007/s00259-024-07017-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39688698 No abstract available.
Aggressive Lymphoma after CD19 CAR T-Cell Therapy.
Kobbe G, Brüggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, Libertini S, Menssen HD, Maier HJ, Ulrich P, Gao J, Bruch PM, Liebers N, Radujkovic A, Seifert M, Schniederjohann C, Paramasivam N, Fitzgerald D, Seidel M, Esposito I, Germing U, Cadeddu RP, Nachtkamp K, Jäger P, Ulrych T, Fischer JC, Rox JM, Giesel F, Koch R, Antoch G, Distler JHW, Meuth SG, Jacobsen M, Hübschmann D, Lu J, Iaccarino I, Haas S, Damm F, Dietrich S. Kobbe G, et al. Among authors: giesel f. N Engl J Med. 2024 Oct 3;391(13):1217-1226. doi: 10.1056/NEJMoa2402730. N Engl J Med. 2024. PMID: 39589371
A challenging discrimination of an intensely [18F]PSMA-1007-avid solitary lesion at the skull base in a patient with biochemical recurrence of prostate cancer.
Novruzov E, Niegisch G, Pauck D, Schmitt D, Kuhlmann J, Beseoglu K, Antoch G, Schimmöller L, Giesel FL, Mamlins E. Novruzov E, et al. Among authors: giesel fl. BJR Case Rep. 2024 Nov 1;10(6):uaae041. doi: 10.1093/bjrcr/uaae041. eCollection 2024 Nov. BJR Case Rep. 2024. PMID: 39553424 Free PMC article.
Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models.
Abe K, Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Naka S, Ooe K, Toyoshima A, Giesel F, Usui T, Masunaga N, Mishima C, Tsukabe M, Yoshinami T, Sota Y, Miyake T, Tanei T, Shimoda M, Shimazu K. Abe K, et al. Among authors: giesel f. Int J Mol Sci. 2024 Oct 28;25(21):11567. doi: 10.3390/ijms252111567. Int J Mol Sci. 2024. PMID: 39519118 Free PMC article.
Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study.
Glemser PA, Freitag M, Kovacs B, Netzer N, Dimitrakopoulou-Strauss A, Haberkorn U, Maier-Hein K, Schwab C, Duensing S, Beuthien-Baumann B, Schlemmer HP, Bonekamp D, Giesel F, Sachpekidis C. Glemser PA, et al. Among authors: giesel f. EJNMMI Rep. 2024 Nov 8;8(1):37. doi: 10.1186/s41824-024-00225-5. EJNMMI Rep. 2024. PMID: 39510993 Free PMC article.
Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
Helisch A, Kratochwil C, Kleist C, Krämer S, Rosales Castillo JJ, Dendl K, Rathke H, von Goetze I, Schreckenberger M, Jäger D, Lindner T, Mier W, Giesel F, Haberkorn U, Röhrich M. Helisch A, et al. Among authors: giesel f. J Nucl Med. 2024 Dec 3;65(12):1917-1922. doi: 10.2967/jnumed.124.268386. J Nucl Med. 2024. PMID: 39477492
Impact of 18F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
Jannusch K, Umutlu L, Kirchner J, Bruckmann NM, Morawitz J, Herrmann K, Fendler WP, Bittner AK, Hoffmann O, Mohrmann S, Ruckhäberle E, Stuschke M, Schmid W, Giesel F, Häberle L, Esposito I, Budach W, Grueneisen J, Matuschek C, Kowall B, Stang A, Antoch G, Buchbender C. Jannusch K, et al. Among authors: giesel f. J Nucl Med. 2024 Dec 3;65(12):1855-1861. doi: 10.2967/jnumed.124.268065. J Nucl Med. 2024. PMID: 39389629 Clinical Trial.
333 results